Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

58.93 +0.39 (+0.67%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

44 45 Next >

Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗

May 16, 2024

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

Via InvestorPlace

Topics Intellectual Property

Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 ↗

May 14, 2024

These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet.

Via InvestorPlace

Amazon Pours ~$1.3B Investment Into French Operations: Report ↗

May 13, 2024

Amazon's €1.2 billion investment marks a significant stride in bolstering its French presence, promising 3,000 new jobs. The move aligns with France's push for tech investment, showcased at the 'Choose...

Via Benzinga

Topics Artificial Intelligence

FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It ↗

May 10, 2024

FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported.

Via Benzinga

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗

April 29, 2024

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.

Via Benzinga

Topics Stocks

Peering Into GSK's Recent Short Interest ↗

March 26, 2024

Via Benzinga

Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine ↗

May 10, 2024

The FDA hasn't said there are any vaccine effectiveness, safety or quality issues that would prevent approval, Moderna says.

Via Investor's Business Daily

Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 ↗

May 09, 2024

Via Benzinga

Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac ↗

May 08, 2024

Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing.

Via Benzinga

Topics Lawsuit

Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout? ↗

May 02, 2024

Moderna is forming its first base in over a year. Could shares top a buy point on the company's sales beat?

Via Investor's Business Daily

7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024 ↗

May 01, 2024

While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing.

Via InvestorPlace

GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q1 2024 ↗

May 01, 2024

GSK stock results show that GSK beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook ↗

May 01, 2024

Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix....

Via Benzinga

Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer Rally ↗

May 01, 2024

A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc.‘s (NASDAQ:AMD)

Via Benzinga

Topics Economy

Forget the Fed. These 3 Stocks Will Soar No Matter What ↗

April 29, 2024

The Fed's actions will have little impact on some stocks. Here are three excellent stocks that are likely to be unaffected by the Fed.

Via InvestorPlace

Topics Economy

COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle ↗

April 26, 2024

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent...

Via Benzinga

Topics Intellectual Property Lawsuit

What's Going On With Pfizer Stock On Thursday? ↗

April 25, 2024

GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.

Via Benzinga

Topics Intellectual Property

Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges ↗

April 19, 2024

Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory...

Via Benzinga

Topics Brexit

Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future ↗

April 18, 2024

Anne Wojcicki, CEO of 23andMe mulls taking the genetics company private amid market challenges. With declining revenue and a focus shift to drug development, the move seeks funding for potential...

Via Benzinga

GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years ↗

April 17, 2024

Lasting protection against shingles for adults over 50 with GSK's RZV vaccine. New data from ZOSTER-049 trial reveals over a decade of high efficacy. Plus, GSK's oral antibiotic, gepotidacin, shows...

Via Benzinga

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields ↗

April 11, 2024

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Down 75%. Is Agenus Stock a Buy on the Dip? ↗

April 08, 2024

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.

Via The Motley Fool

CureVac, GS Partner Release Data On Influenza Vaccine Study ↗

April 04, 2024

CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A...

Via Benzinga

In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster ↗

April 04, 2024

Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed.

Via Benzinga

Topics Lawsuit

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment

April 03, 2024

Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia

Via MarketBeat

2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now? ↗

April 03, 2024

These stocks could rocket higher, but they also present significant risks.

Via The Motley Fool

Russell 2000 Index Best And Worst Performing Stocks Of 2024 ↗

April 02, 2024

The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024.

Via Talk Markets

Topics Stocks

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗

March 28, 2024

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

Via Investor's Business Daily

Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead? ↗

March 24, 2024

Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.

Via The Motley Fool

Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month ↗

March 21, 2024

GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid...

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Starting at $3.75/week.

Subscribe Today